Liver Neoplasm Clinical Trial
— ROCK-RTOfficial title:
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).
Status | Recruiting |
Enrollment | 50 |
Est. completion date | October 31, 2026 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site. - Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan - The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking. - Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited) Exclusion Criteria: - Less than 18 years of age - Minimum image dataset is not available - Image dataset is not in a compatible format |
Country | Name | City | State |
---|---|---|---|
Australia | Peter MacCallum Cancer Centre | Melbourne | Victoria |
Australia | The Austin Hospital | Melbourne | Victoria |
Australia | Calvary Mater Newcastle Hospital | Waratah | New South Wales |
Australia | Westmead Hospital | Westmead | New South Wales |
Australia | Princess Alexandra Hospital | Woolloongabba | Queensland |
Lead Sponsor | Collaborator |
---|---|
University of Sydney | Austin Health, Calvary Mater Newcastle, Australia, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia, Western Sydney Local Health District |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of images that have contrast mass detection by software | Proportion of images in which kilovoltage intrafraction monitoring software detects contrast agent mass on CBCT and intra-treatment images | 2 weeks | |
Primary | Average difference between software and ground truth measure | Average difference (mm) of location of contrast mass detection on CBCT and treatment images by KIM software compared to the ground truth in each of the horizontal and vertical directions. | 2 weeks | |
Primary | Standard deviation of difference between software and ground truth measure | Standard deviation difference (mm) of location of contrast mass detection on CBCT and treatment images by KIM software compared to the ground truth in each of the horizontal and vertical directions. | 2 weeks | |
Secondary | Modelling of patient or treatment features that contributed to the success or failure of the KIM method | Using the KIM success rate (primary hypothesis) and patient CT imaging features (contrast agent density, size, shape and location, patient size etc) a generalised linear model, or appropriate alternative, will be used to identity univariate and multivariate patient or treatment features that contributed to the success or failure of the KIM method. Selected features will be identified and developed into a model. If the model predicts the likelihood of KIM success in at least 85% of the patients then the study will be deemed to have achieved the hypothesis. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Terminated |
NCT04702230 -
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
|
||
Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
Withdrawn |
NCT02599909 -
Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
|
||
Terminated |
NCT03998033 -
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT04010071 -
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
|
Phase 2 | |
Recruiting |
NCT04864054 -
T-Cell Therapy (ECT204) in Adults With Advanced HCC
|
Phase 2 | |
Terminated |
NCT04187937 -
Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections
|
N/A | |
Completed |
NCT02471313 -
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
|
Phase 2 | |
Completed |
NCT00001576 -
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
|
Phase 1 | |
Recruiting |
NCT01542281 -
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer
|
N/A | |
Recruiting |
NCT03803436 -
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
|
Phase 2 | |
Completed |
NCT05495529 -
Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
|
||
Recruiting |
NCT02632864 -
Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial
|
Phase 2 | |
Completed |
NCT02571946 -
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
|
N/A | |
Not yet recruiting |
NCT01180088 -
Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy
|
N/A | |
Withdrawn |
NCT00510627 -
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
|
Phase 4 | |
Completed |
NCT05848947 -
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
|
Phase 4 | |
Not yet recruiting |
NCT05723705 -
Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
|
||
Terminated |
NCT04502082 -
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
|
Phase 1/Phase 2 |